SCISPARC LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.23 USD | +0.82% |
|
-8.89% | -74.80% |
| Apr. 11 | SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd. | CI |
| Apr. 01 | SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -74.80% | 3.33M | |
| +17.97% | 42.77B | |
| +20.21% | 22.23B | |
| +12.68% | 14.44B | |
| +12.19% | 13.05B | |
| +35.45% | 11.59B | |
| -8.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +5.03% | 4.97B |
- Stock Market
- Equities
- SPRC Stock
- News SciSparc Ltd.
- SpiSparc to Raise $10 Million via Private Placement
